Analysis of HLA-A24-restricted peptides of carcinoembryonic antigen using a novel structure-based peptide-HLA docking algorithm
Yoji Nakamura
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
National Research Institute of Fisheries Science, Fisheries Research Agency, Fukuura, Kanazawa, Yokohama, Kanagawa
Search for more papers by this authorSachiko Tai
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
Search for more papers by this authorChie Oshita
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
Search for more papers by this authorAkira Iizuka
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
Search for more papers by this authorTadashi Ashizawa
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
Search for more papers by this authorHaruhiko Kondo
Division of Thoracic Surgery, Shizuoka Cancer Center Hospital, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan
Search for more papers by this authorKen Yamaguchi
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
Search for more papers by this authorCorresponding Author
Yasuto Akiyama
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
To whom correspondence should be addressed. E-mail: [email protected]Search for more papers by this authorYoji Nakamura
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
National Research Institute of Fisheries Science, Fisheries Research Agency, Fukuura, Kanazawa, Yokohama, Kanagawa
Search for more papers by this authorSachiko Tai
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
Search for more papers by this authorChie Oshita
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
Search for more papers by this authorAkira Iizuka
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
Search for more papers by this authorTadashi Ashizawa
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
Search for more papers by this authorHaruhiko Kondo
Division of Thoracic Surgery, Shizuoka Cancer Center Hospital, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan
Search for more papers by this authorKen Yamaguchi
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
Search for more papers by this authorCorresponding Author
Yasuto Akiyama
Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka
To whom correspondence should be addressed. E-mail: [email protected]Search for more papers by this authorAbstract
Carcinoembryonic antigen (CEA) is a very common tumor marker because many types of solid cancer usually produce a variety of CEA and a highly sensitive measuring kit has been developed. However, immunological responses associated with CEA have not been fully characterized, and specifically a weak immunogenicity of CEA protein as a tumor antigen is reported in human leukocyte antigen (HLA)-A24-restricted CEA peptide-based cancer immunotherapy. These observations demonstrated that immunogenic and potent HLA-A24-restricted CTL epitope peptides derived from CEA protein are seemingly difficult to predict using a conventional bioinformatics approach based on primary amino acid sequence. In the present study, we developed an in silico docking simulation assay system of binding affinity between HLA-A24 protein and A24-restricted peptides using two software packages, AutoDock and MODELLER, and a crystal structure of HLA-A24 protein obtained from the Protein Data Bank. We compared the current assay system with HLA–peptide binding predictions of the bioinformatics and molecular analysis section (BIMAS) in terms of the prediction capability using MHC stabilization and peptide-stimulated CTL induction assays for CEA and other HLA-A24 peptides. The MHC stabilization score was inversely correlated with the affinity calculated in the docking simulation alone (r = −0.589, P = 0.015), not with BIMAS score or the IFN-γ production index. On the other hand, BIMAS was not significantly correlated with any other parameters. These results suggested that our in silico assay system has potential advantages in efficiency of epitope prediction over BIMAS and ease of use for bioinformaticians. (Cancer Sci 2011; 102: 690–696)
References
- 1 Onizawa S, Watanabe S, Yagura T, Yasutomi M, Yamamura Y. Radioimmunoassay of carcinoembryonic antigen and clinical significance of its level in plasma. Gann 1976; 67: 371–8.
- 2 Tsai HL, Chu KS, Huang YH et al. Predictive factors of early relapse in UICC stage I–III colorectal cancer patients after curative resection. J Surg Oncol 2009; 100: 736–43.
- 3 Jokerst JV, Raamanathan A, Christodoulides N et al. Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. Biosens Bioelectron 2009; 24: 3622–9.
- 4 Kawashima I, Hudson SJ, Tsai V et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998; 59: 1–14.
- 5 Kavanagh B, Ko A, Venook A et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 2007; 30: 762–72.
- 6 Pickford WJ, Watson AJ, Barker RN. Different forms of helper tolerance to carcinoembryonic antigen: ignorance and regulation. Clin Cancer Res 2007; 13: 4528–37.
- 7 Crosti M, Longhi R, Consogbo G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4 + T cells of lung cancer patients. J Immunol 2006; 176: 5093–9.
- 8 Iero M, Squarcina P, Romero P et al. Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. Cancer Immunol Immunother 2007; 56: 1979–91.
- 9
Nukaya I,
Yasumoto M,
Iwasaki T
et al.
Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte.
Int J Cancer
1999; 80: 92–7.
10.1002/(SICI)1097-0215(19990105)80:1<92::AID-IJC18>3.0.CO;2-M CAS PubMed Web of Science® Google Scholar
- 10 Matsuda K, Tsunoda T, Tanaka H et al. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 2004; 53: 609–16.
- 11 Itoh T, Ueda Y, Kawashima I et al. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother 2002; 51: 99–106.
- 12 Ueda Y, Itoh T, Nukaya I et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 2004; 24: 909–17.
- 13 Ojima T, Iwahashi M, Nakamura M et al. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA. Int J Oncol 2008; 32: 459–66.
- 14 Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779–815.
- 15
Morris GM,
Goodsell DS,
Halliday RS
et al.
Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function.
J Comput Chem
1998; 19: 1639–62.
10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B CAS Web of Science® Google Scholar
- 16 Berman HM, Battistuz T, Bhat TN et al. The Protein Data Bank. Acta Crystallogr D Biol Crystallogr 2002; 58: 899–907.
- 17 Knorr R, Trzeciak A, Bannwarth W, Gillessen D. New coupling reagents in peptide chemistry. Tetrahedron Lett 1989; 30: 1927–30.
- 18 Kuzushima K, Hayashi N, Kimura H, Tsurumi T. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001; 98: 1872–81.
- 19 Abbas AK, Lichtman AH, Pillai S. The major histocompatibility complex. In: AK Abbas, AH Lichtman, S Pillai, eds. Cellular and Molecular Immunology, 6th edn. Philadelphia: Saunders, 2010; 97–111.
- 20 Sieker F, May A, Zacharias M. Predicting affinity and specificity of antigenic peptide binding to major histocompatibility class I molecules. Curr Protein Pept Sci 2009; 10: 286–96.
- 21 Schiewe AJ, Hawworth IS. Structure-based prediction of MHC-peptide association: algorithm comparison and application to cancer vaccine design. J Mol Graph Model 2007; 26: 667–75.
- 22 Shastri N. Needles in haystacks: identifying specific peptide antigens for T cells. Curr Opin Immunol 1996; 8: 271–7.
- 23 Pelte C, Cherepnev G, Wang Y, Schoenemann C, Volk HD, Kern F. Random screening of proteins for HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201. J Immunol 2004; 172: 6783–9.
- 24 Logean A, Rognan D. Recovery of known T-cell epitopes by computational scanning of a viral genome. J Comput Aided Mol Des 2002; 16: 229–43.
- 25 Desmet J, Meersseman G, Boutonnet N et al. Anchor profiles of HLA-specific peptides: analysis by a novel affinity scoring method and experimental validation. Proteins 2005; 58: 53–69.
- 26 Fuhrmann J, Rurainski A, Lenhof HP, Neumann D. A new Lamarckian genetic algorithm for flexible ligand-receptor docking. J Comput Chem 2010; 31: 1911–8.
- 27 Kazansky DB. Intrathymic selection: new insight into tumor immunology. Adv Exp Med Biol 2007; 601: 133–44.
- 28 Bui HH, Schiewe AJ, von Grafenstein H, Haworth LS. Structural prediction of peptides binding to MHC class I molecules. Proteins 2006; 63: 43–52.
- 29 Rammensee HG, Bachmann J, Emmerich NN, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptides motifs. Immunogenetics 1999; 50: 213–9.
- 30 Buus S, Lauemoller SL, Worning P et al. Sensitive quantitative predictions of peptide-MHC binding by a ‘Query by Committee’ artificial neural network approach. Tissue Antigens 2003; 62: 378–84.